▶ SERMORELIN · SUBTOPIC · MECHANISM
SERMORELIN Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Synthetic 29-amino-acid fragment representing the native bioactive N-terminus of human GHRH. Engages pituitary GHRH receptors to trigger endogenous GH release. Previously FDA-approved as Geref (pediatric GH deficiency) before withdrawal from US market for commercial reasons.
PHARMACOKINETIC HALF-LIFE
Reported half-life for SERMORELIN: ~10-20 minutes. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
SERMORELIN is a defined sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
SERMORELIN is tagged in 1 mechanism category on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: GH-axis reference and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Geref Phase 3 trials demonstrated GH-stimulating activity in pediatric growth hormone deficiency, supporting 1997 FDA approval.
Adult clinical literature reports modest IGF-1 elevation with chronic dosing.
Limited Western RCT evidence in healthy older adults.
MECHANISM Q+A
▶ What is sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide representing the native bioactive N-terminus of human growth-hormone-releasing hormone (GHRH(1-29)). It engages pituitary GHRH receptors to trigger endogenous GH release.
▶ Sermorelin vs CJC-1295 · what's the difference?
Sermorelin is the unmodified native GHRH(1-29) sequence with a short half-life (~10-20 min) and rapid DPP-IV cleavage. CJC-1295 is the same parent sequence with four stabilizing amino-acid substitutions that resist DPP-IV cleavage (Mod GRF 1-29, No DAC variant). CJC-1295 with DAC adds a covalent albumin-binding linker for ~1-week half-life.
▶ What is the half-life of sermorelin?
Approximately 10-20 minutes plasma half-life. The unmodified sequence is rapidly cleaved by DPP-IV. Frequent dosing or paired administration with a ghrelin-receptor agonist is used in research to amplify the GH pulse.
▶ How does sermorelin work?
Sermorelin binds the GHRH receptor (GHRH-R) on anterior-pituitary somatotrophs and triggers cAMP-mediated release of stored growth hormone. The short half-life produces a pulse closer to the natural pulsatile rhythm than longer-acting analogs.
▶ Sermorelin vs ipamorelin · is one better?
Different mechanisms. Sermorelin acts on the GHRH receptor; ipamorelin acts on the ghrelin / GHS-R1a receptor. The two pathways are complementary; research protocols often pair a GHRH analog (sermorelin or CJC-1295) with a ghrelin-receptor agonist (ipamorelin) to amplify the GH pulse via dual-pathway activation.
CITED LITERATURE
- Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging 2006. PMID 18046871. link
- FDA Center for Drug Evaluation and Research. FDA approval of sermorelin (Geref) for pediatric growth hormone deficiency. FDA approval letter 1997. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25